Clean Yield Group Sells 1,789 Shares of Amgen, Inc. (NASDAQ:AMGN)

Share on StockTwits

Clean Yield Group decreased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 10.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,499 shares of the medical research company’s stock after selling 1,789 shares during the period. Amgen makes up 1.2% of Clean Yield Group’s investment portfolio, making the stock its 25th largest holding. Clean Yield Group’s holdings in Amgen were worth $3,736,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. First National Bank of Omaha boosted its stake in Amgen by 14.2% during the fourth quarter. First National Bank of Omaha now owns 30,992 shares of the medical research company’s stock worth $7,472,000 after acquiring an additional 3,859 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Amgen by 1.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 39,507 shares of the medical research company’s stock worth $9,524,000 after acquiring an additional 411 shares in the last quarter. Brave Asset Management Inc. boosted its stake in Amgen by 0.8% during the fourth quarter. Brave Asset Management Inc. now owns 12,968 shares of the medical research company’s stock worth $3,126,000 after acquiring an additional 103 shares in the last quarter. Orrstown Financial Services Inc. boosted its stake in Amgen by 1,729.9% during the fourth quarter. Orrstown Financial Services Inc. now owns 1,958 shares of the medical research company’s stock worth $473,000 after acquiring an additional 1,851 shares in the last quarter. Finally, Inlet Private Wealth LLC boosted its stake in Amgen by 0.4% during the fourth quarter. Inlet Private Wealth LLC now owns 26,463 shares of the medical research company’s stock worth $6,379,000 after acquiring an additional 100 shares in the last quarter. 76.58% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Amgen stock opened at $241.49 on Friday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 2.59 and a current ratio of 2.89. The stock has a market capitalization of $143.49 billion, a PE ratio of 16.77, a price-to-earnings-growth ratio of 2.08 and a beta of 1.11. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $244.99. The company has a 50-day simple moving average of $238.58 and a two-hundred day simple moving average of $209.37.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.53 by $0.13. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The business’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same period in the previous year, the company earned $3.69 earnings per share. As a group, equities research analysts forecast that Amgen, Inc. will post 14.58 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 14th will be issued a $1.60 dividend. The ex-dividend date is Thursday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 annualized dividend and a yield of 2.65%. Amgen’s payout ratio is 40.28%.

In other news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total transaction of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 9,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $230.54, for a total transaction of $2,074,860.00. The disclosure for this sale can be found here. Insiders sold 18,162 shares of company stock valued at $4,214,030 over the last ninety days. Corporate insiders own 0.25% of the company’s stock.

Several research firms recently commented on AMGN. Cowen boosted their price objective on shares of Amgen from $253.00 to $277.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. Sanford C. Bernstein began coverage on shares of Amgen in a research note on Monday, October 14th. They set an “outperform” rating on the stock. Credit Suisse Group boosted their price objective on shares of Amgen from $235.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, December 13th. Leerink Swann boosted their price objective on shares of Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley dropped their price objective on shares of Amgen from $280.00 to $277.00 and set an “overweight” rating on the stock in a research note on Friday. Eleven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $235.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: What causes a stock to be most active?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GAM Holding AG Decreases Holdings in Lear Co.
GAM Holding AG Decreases Holdings in Lear Co.
GAM Holding AG Makes New Investment in FirstEnergy Corp.
GAM Holding AG Makes New Investment in FirstEnergy Corp.
GAM Holding AG Sells 1,916 Shares of Constellation Brands, Inc.
GAM Holding AG Sells 1,916 Shares of Constellation Brands, Inc.
GAM Holding AG Reduces Stock Position in Philip Morris International Inc.
GAM Holding AG Reduces Stock Position in Philip Morris International Inc.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
Cracker Barrel Old Country Store, Inc.  Shares Sold by GAM Holding AG
Cracker Barrel Old Country Store, Inc. Shares Sold by GAM Holding AG


 
© 2006-2020 Zolmax.